Synaptogenix collaborating with LSU Health New Orleans in spinal cord injury

Synaptogenix announced a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for pre-clinical testing of the company’s polyunsaturated fatty acid analogs as a treatment for spinal cord injury. The USPTO recently issued a patent covering its family of analogs. The studies will compare the analogs with Bryostatin in SCI. Synaptogenix holds exclusive rights to its PUFA analogs pursuant to a licensing agreement with Cognitive Research Enterprises, formerly known as the Blanchette Rockefeller Neurosciences Institute.